Exhibit 99.2

                      Press Release dated February 25, 2005

Thomas Striepe elected new Director

Cash contribution of $375,000 through issuance of new shares

Witten, Germany, February 25, 2005 - In February 2005, Sangui Biotech
International, Inc., sold 4,500,000 restricted shares of common stock for
aggregate proceeds of $275,000. As previously announced, the company had sold
2,000,000 shares of common stock to two German investors in November, 2004 for a
total purchasing price of $100,000. "These investments will help the company to
bridge the time gap until we can generate revenues from product sales which we
expect to begin in the third and fourth quarters of the current fiscal year",
Wolfgang Barnikol, the president of the company, said. In addition, the company
entered into a Consulting Agreement under which Joachim Fleing would provide
certain investor and public relation services to the company. In consideration
for such services Sangui issued 200,000 restricted shares of common stock at a
price of $0.0875 per share. On closing of these transactions the total number of
Sangui Common Stock will amount to 48,355,363 shares issued and outstanding.

Sangui Directors Christoph Ludz and Markus Volpers resigned effective February
7, 2005. The Board appointed Thomas Striepe, Vice President Accounting and
Controlling of Dr. Ludz GmbH, Hamburg, as a new director. The Board of directors
now consists of Wolfgang Barnikol, Joachim Lutz, Thomas Striepe, and Joachim
Fleing.

Thomas Striepe (born 1961) is Vice President Accounting and Controlling at Dr.
Ludz GmbH, Hamburg, Germany, a financial services company. Prior to joining Dr.
Ludz GmbH in 2004, he held management positions in the accounting departments of
several German and German brnaches of international corporations, among them
Joh. Benckiser GmbH, Interturbine Germany GmbH, Hagen Deutschland GmbH & Co. KG.
He holds an MBA of Hamburg University.

For more information please contact:

Joachim Fleing
Phone: +49 (160) 741 27 17
Fax: +49 (2302) 915 191
e-mail: fleing@sangui.de

This news release includes statements, other than historical fact, that may be
deemed forward-looking. These statements may be accompanied by words such as
"believe," "estimate," "project," "expect," "anticipate," or "predict" that
conveys the uncertainty of future events or outcomes. These statements are based
on assumptions that the Company believes are reasonable; however, many factors
could cause the Company's actual results in the future to differ materially from
the forward-looking statements made herein and in any other documents or oral
presentations made by, or on behalf of, the Company. Important factors which
could cause actual results to differ materially from those in forward-looking
statements include, among others, the ability to obtain additional financing,
which is not assured; rapid technological developments and changes; problems in
developments of the Company's products; price and product competition by
competitors; general economic conditions; and factors discussed in the Company's
SEC filings. Shareholders are cautioned that the forward-looking statements are
not guarantees of future performance and that developments different from those
projected in the forward-looking statements can be expected. Sangui does not
intend (and is not legally obligated) to update publicly any forward-looking
statements.